The Experimental Study Of Drug-eluting Stent Manufactured In China For Prevention Of Restenosis In Porcine Artery Coronary Model

BackgroudThe long-term clinical efficacy of intracoronary stenting is limited by restenosis, which occurs in 15% to 30% of patients. No systemic or catheter-based local vascular pharmacologic therapy including brachy-therapy effectively reduced in-stent restenosis. Drug-eluting stent (DES) enable to deliver the drug which can intervene pathological process of restenosis to target lesion locally, its effects of prevention ISR have been proved by many animal and clinical studies. Cypher(Cordis) and Taxus(Boston Scientific) stents are the major product in the market. So far most of DES are imported from US or European countries. It is necessary to approach a way to manufacture the Drug-eluting stent in China and to improve the performance of the DES, including stent platform, polymer coating and drugs.ObjectivesIn order to improve the performance of DES and to manufacture...